Joel L. Johnson

The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent

Emile R. Mohler, Christie M. Ballantyne, Michael H. Davidson et al. · Journal of the American College of Cardiology · 2008 · 209 citations

Medicine, Cardiology, Pharmacology +14

Study design and rationale for the Stabilization of pLaques usIng Darapladib—Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome

Michelle L. O’Donoghue, Eugene Braunwald, Harvey D. White et al. · American Heart Journal · 2011 · 91 citations

Medicine, Cardiology, Clinical Sciences +17

Effect of Darapladib Treatment on Endarterectomy Carotid Plaque Lipoprotein-Associated Phospholipase A2 Activity: A Randomized, Controlled Trial

Joel L. Johnson, Yi Shi, Rose Snipes et al. · PLoS ONE · 2014 · 27 citations · Full text

Medicine, Pharmacotherapy, Cardiovascular Pharmacotherapy +16

Peripheral artery disease, biomarkers, and darapladib

Jeffrey S. Berger, Christie M. Ballantyne, Michael H. Davidson et al. · American Heart Journal · 2011 · 24 citations · Full text

Medicine, Cardiology, Clinical Sciences +12